Table 1.
Characteristics of Patients Available at 1 year (n=52)
| No Delirium Episode (n=29) n (%) | Delirium Episode1 (n=23) n (%) | P Value | |
|---|---|---|---|
| Age at study entry | 0.28 | ||
| 22-35 | 12 (41.4) | 5 (21.7) | |
| 36-45 | 9 (31.0) | 7 (30.4) | |
| 46-55 | 6 (20.7) | 6 (26.1) | |
| 56-62 | 2 (6.9) | 5 (21.7) | |
| Gender | 0.11 | ||
| Male | 19 (65.5) | 10 (43.5) | |
| Female | 10 (34.5) | 13 (56.5) | |
| Race | 0.30 | ||
| White | 27 (93.1) | 23 (100%) | |
| Hispanic | 1 (3.4) | 0 (0) | |
| Other | 1 (3.4) | 0 (0) | |
| Diagnosis | 0.01 | ||
| CML | 17 (58.6) | 10 (43.5) | |
| ALL or AML | 5 (17.2) | 3 (13.0) | |
| BR or OV | (3.4) | 7 (30.4) | |
| MDS or MM | 4 (13.8) | 0 (0) | |
| NHL | 2 (6.9) | 3 (13.0) | |
| Disease stage2 | 0.47 | ||
| Less advanced | 15 (51.7) | 10 (43.5) | |
| More advanced | 13 (44.8) | 13 (56.5) | |
| Source of Stem Cells | 0.06 | ||
| Bone Marrow | 24 (82.8) | 13 (56.5) | |
| Stem Cell | 5 (17.2) | 10 (43.5) | |
| Donor Type | 0.02 | ||
| Allogeneic | 27 (93.1) | 15 (65.2) | |
| Autologous | 2 (6.9) | 8 (34.8) | |
| GVHD Prophylaxis | 0.03 | ||
| CSP or Tacrolimus and Methotrexate | 22 (75.9) | 12 (52.2) | |
| Methotrexate alone | 2 (6.9) | 8 (43.8) | |
| RFT5.dgA | 3 (10.3) | 3 (13.0) | |
| BC-3 | 2 (6.9) | 0 (0) | |
| Systemic Chemotherapy before HCT | 0.34 | ||
| Hydroxyurea only or none | 13 (44.8) | 7 (30.4) | |
| Interferon with or without hydroxyurea | 6 (20.7) | 4 (17.4) | |
| Chemo other than interferon or hydroxyurea | 9 (31.0) | 12 (52.2) | |
| Cranial Irradiation or Intrathecal Chemotherapy before HCT | 0.80 | ||
| Yes | 3 (10.3) | 3 (13.0) | |
| None | 25 (86.2) | 20 (87.0) | |
| Conditioning with Total Body Irradiation | 0.62 | ||
| ≤ 1200 cGy | 7 (24.2) | 7 (30.4) | |
| > 1200 cGy | 9 (31.0) | 6 (26.1) | |
| None | 13 (44.8) | 10 (43.5) | |
| Chronic GVHD Extent | 0.22 | ||
| Extensive | 23 (79.3) | 14 (60.9) | |
| Limited or None | 6 (20.7) | 9 (39.1) | |
| GVHD Treatment Medications | 0.48 | ||
| Glucocorticoids | 22 (75.9) | 20 (87.0) | |
| Other or none | 7 (24.1) | 3 (13.0) | |
| Relapse at 6 months | 0.69 | ||
| Relapse since baseline | 2 (6.9) | 1 (4.3) | |
| No relapse | 27 (93.1) | 22 (95.7) | |
| Relapse at 1 year | 0.62 | ||
| Relapse since 6 months | 3 (10.3) | 1 (4.3) | |
| No relapse | 26 (89.7) | 22 (95.7) | |
| Mean (SD) | Mean (SD) | ||
| Pretransplantation Charlson Comorbidity Score | 2.3 (1.1) | 2.4 (1.3) | 0.72 |
CML = chronic myeloid leukemia, ALL = acute lymphoblastic leukemia, AML = acute myeloid leukemia, BR = breast carcinoma, OV = ovarian carcinoma, MDS = myelodysplasia, MM = multiple myeloma, NHL = non-Hodgkin's lymphoma, GVHD = Graft-versus-host disease, CSP = cyclosporine, RFT5.dgA = CD25-specific immunotoxin, BC-3 = CD3-specific antibody
Delirium episode group includes patients with 2 out of 3 consecutive assessments with DRS>12.
Less advanced disease was defined as acute lymphoblastic leukemia or acute myeloid leukemia in first remission; chronic myeloid leukemia in a chronic phase; non-Hodgkin's lymphoma in first remission, untreated first recurrence, or second remission. More advanced disease included all other stages of these diseases, all other types of hematologic malignancies, breast carcinoma ≥ stage II, and ovarian carcinoma